Anesiva's Zingo gains approval for use in adults and is available for licensing
This article was originally published in Scrip
Executive Summary
Although Anesivahas halted the marketing of its intradermal analgesic for blood draw pain, Zingo ((lidocaine powder), mainly because of production issues (Scrip Online, November 11th, 2008), the regulatory process has continued.